A+ R A-

Treatment of Waldenstroms Macroglobulinemia

Please select from the following list of abstracts, representing the presentations given in Stockholm 2008 (IWWM-5) Session 5:

Rituximab based therapies in Waldenström's macroglobulinemia. M.A. Dimopoulos, MD, E. Kastritis, MD, M. Gavriatopoulou, MD, M. Migkou, MD, M. Roussou, MD , E. Eleftherakis-Papaiakovou, MD, E. Terpos, MD. Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, GREECE.

Maintenance rituximab in indolent lymphoma. Michele Ghielmini, Oncology Institute of Southern Switzerland and Swiss Group for Clinical Cancer Research, Bellinzona, SWITZERLAND.

Fludarabine-based Combination therapies for Waldenströms macroglobulinemia. Enrica Morra, Dept. of Hematology, Niguarda Ca’ Granda Hospital, Milano, ITALY.

Long Term Responses to Fludarabine and Rituximab in Waldenström's Macroglobulinemia. Andrew Branagan, Leukothea Ioakimidis, Jacob Soumerai, Christopher Patterson, Parveen Wasi, Christos Emmanouilides, Stanley R. Frankel, T. Andrew Lister, Pierre Morel, Jeffrey Matous, Stephanie A. Gregory, Eva Kimby, Steven P. Treon. Dana-Farber Cancer Institute, Boston, MA, USA; McMaster University, Hamilton, Ontario, CANADA, Interbalkan Hospital, Pylaia, GREECE, University of Maryland, Greenbaum Cancer Center, Baltimore MD, USA; Centre for Medical Oncology, Barts and the London School of Medicine, London, UNITED KINGDOM; Service d'Hematologie Clinique, Lens, FRANCE; Rocky Mountain Cancer Center, Denver, CO, USA; Rush University Hospital, Chicago, IL, USA; Hematology Center, Karolinska Institutet, Stockholm, SWEDEN.

Bortezomib in Relapsed/Refractory Waldenström’s macroglobulinemia. Christine Chen, C. Tom Kouroukis, Darrell White, Michael Voralia, Edward Stadtmauer, A.Keith Stewart, John J.Wright, Jean Powers, Wendy Walsh, Elizabeth Eisenhauer Princess Margaret Hospital, University of Toronto, Ontario, CANADA.

Bortezomib alone and in combination with Rituximab in patients with Waldenström’s Macroglobulinaemia. A Rohatiner, A Agathocleous, S Rule, P Johnson, J Radford, S Strauss, A Lister  CR-UK Medical Oncology Unit, St. Bartholomew’s Hospital, London.  Dept. of Haematology, Derriford Hospital, Plymouth.  CR-UK Clincal Centre, Southampton General Hospital, Southampton. CR-UK Dept. of Medical Oncology, Christie Hospital and University of Manchester, Manchester, UNITED KINGDOM.

Primary Therapy of Waldenström’s Macroglobulinemia with Bortezomib, Dexamethasone and Rituximab: Results of WMCTG Clinical Trial 05-180. S.P. Treon, L. Ioakimidis, J.D. Soumerai, C.J. Patterson,  M.A. Willen,  J. Matous, J. Mattern II, J. Diener, G. Keogh, T.J. Myers, A. Birner, A. Boral, and I. Ghobrial. Bing Center for Waldenström’s Macroglobulinemia, Dana Farber Cancer Institute, Boston MA; New York Hematology and Oncology, Latham NY; Rocky Mountain Cancer Center, Denver CO; Virginia Oncology Associates, Newport News VA; Littleton Regional Hospital, Littleton NH; Charleston Hematology Oncology, Charleston SC; and Millenium Pharmaceuticals, Inc., Cambridge MA, USA.

The Emerging Role of Histone Deacetylase Inhibitors in Waldenström‘s Macroglobulinemia. Owen A. O’Connor, The New York Presbyterian Hospital, Columbia University, New York, N.Y., USA.

Stockholm 2008 (IWWM-5)

The 5th International Workshop on WM (IWWM-5) was made possible through the kind and generous unrestricted grants or gifts from the following sponsors:

Peter and Helen Bing Fund for Waldenström's Macroglobulinemia

 

Karen Lee Sobol Foundation

 

Bailey family Foundation for Waldenström's Macroglobulinemia

 

Linda and Edward Nelson Fund for Waldenström's Macroglobulinemia